Compare EUDA & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | ABVC |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Singapore | United States |
| Employees | 123 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.0M | 34.6M |
| IPO Year | N/A | 2009 |
| Metric | EUDA | ABVC |
|---|---|---|
| Price | $21.00 | $1.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $55.00 | N/A |
| AVG Volume (30 Days) | 3.2K | ★ 169.4K |
| Earning Date | 12-19-2023 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $509,589.00 |
| Revenue This Year | $134.73 | N/A |
| Revenue Next Year | $195.03 | N/A |
| P/E Ratio | $123.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.88 |
| 52 Week High | $25.70 | $3.39 |
| Indicator | EUDA | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 69.01 | 35.00 |
| Support Level | $1.38 | $0.96 |
| Resistance Level | $25.70 | $1.15 |
| Average True Range (ATR) | 1.04 | 0.12 |
| MACD | 0.92 | -0.05 |
| Stochastic Oscillator | 90.61 | 8.79 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.